Literature DB >> 23397299

Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination.

Roland Diel1, Robert Loddenkemper, Jean-Pierre Zellweger, Giovanni Sotgiu, Lia D'Ambrosio, Rosella Centis, Marieke J van der Werf, Masoud Dara, Anne Detjen, Peter Gondrie, Lee Reichman, Francesco Blasi, Giovanni Battista Migliori.   

Abstract

The introduction of new rapid diagnostic tools for tuberculosis (TB) and the promising TB drugs pipeline together with the development of a new World Health Organization Strategy post 2015 allows new discussions on how to direct TB control. The European Respiratory Society's European Forum for TB Innovation was created to stimulate discussion on how to best take advantage of old and new opportunities, and advances, to improve TB control and eventually progress towards the elimination of TB. While TB control is aimed at reducing the incidence of TB by early diagnosis and treatment of infectious cases of TB, TB elimination requires focus on sterilising the pool of latently infected individuals, from which future TB cases would be generated. This manuscript describes the three core components that are necessary to implement the elimination strategy fully. 1) Improve diagnosis of latent TB infected individuals. 2) Improve regimens to treat latent TB infection. 3) ensure public health commitment to make both 1) and 2) possible. Old and new evidence is critically described, focusing on the European commitment to reach elimination and on the innovative experiences and best practices available.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397299     DOI: 10.1183/09031936.00205512

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  31 in total

1.  A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

Authors:  Lia D'Ambrosio; Marina Tadolini; Rosella Centis; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 3.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 4.  Diversity and evolution of Mycobacterium tuberculosis: moving to whole-genome-based approaches.

Authors:  Stefan Niemann; Philip Supply
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-04       Impact factor: 6.915

5.  The impact of novel tests for tuberculosis depends on the diagnostic cascade.

Authors:  Amanda Y Sun; Claudia M Denkinger; David W Dowdy
Journal:  Eur Respir J       Date:  2014-09-03       Impact factor: 16.671

6.  Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Deborah Banks-Tripp; Sarah Hashmi; Carrie Kujoth; Dean Schraufnagel
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

Review 7.  Clinical Aspects of Adult Tuberculosis.

Authors:  Robert Loddenkemper; Marc Lipman; Alimuddin Zumla
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-06       Impact factor: 6.915

Review 8.  Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.

Authors:  Roland Diel; Niklas Lampenius; Albert Nienhaus
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

9.  Computational identification and characterization of antigenic properties of Rv3899c of Mycobacterium tuberculosis and its interaction with human leukocyte antigen (HLA).

Authors:  Ritam Das; Kandasamy Eniyan; Urmi Bajpai
Journal:  Immunogenetics       Date:  2021-07-06       Impact factor: 2.846

10.  Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

Authors:  S Bamrah; R Brostrom; F Dorina; L Setik; R Song; L M Kawamura; A Heetderks; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2014-08       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.